Citigroup reiterated coverage on Travere Therapeutics with a new price target

6/11/25 7:31:38 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $32.00 from $35.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TVTX

Date	Price Target	Rating	Analyst
6/11/2025	$30.00	Buy	H.C. Wainwright
6/11/2025	$35.00 → $32.00	Buy	Citigroup
1/10/2025		Overweight	Cantor Fitzgerald
10/21/2024	$9.00 → $27.00	Equal Weight → Overweight	Wells Fargo
10/16/2024		Sector Outperform	Scotiabank
9/9/2024	$25.00	Neutral → Buy	Guggenheim
3/27/2024		Buy → Neutral	Guggenheim
12/5/2023	$7.00 → $10.00	Neutral → Buy	Citigroup